High concordance of BRAF status between primary colorectal tumours and related metastatic sites: Implications for clinical practice

Annals of Oncology

Volumn 21, Issue 7, 2010, Pages 1565-

  Santini, D ^a   Spoto, C ^a   Loupakis, F ^b   Vincenzi, B ^a   Silvestris, N ^c   Cremolini, C ^b   Canestrari, E ^d   Graziano, F ^e   Galluccio, N ^d   Salvatore, L ^b   Caraglia, M ^f   Zito, F A ^c   Colucci, G ^c   Falcone, A ^b   Tonini, G ^a   Ruzzo, A ^d  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^d UNIVERSITY OF URBINO   (Italy)

^e SAN SALVATORE HOSPITAL   (Italy)

^f SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DNA; K RAS PROTEIN;

ADULT; AGED; CLINICAL PRACTICE; COLORECTAL TUMOR; EXON; GENE MUTATION; HUMAN; LETTER; LIVER METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MUTATIONAL ANALYSIS; PRIMARY TUMOR; PRIORITY JOURNAL; WILD TYPE;

EID: 77954259787     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq318     Document Type: Letter

References (5)

1. Lièvre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374-379.
2. Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-5712.
3. Tol J, Nagtegaal ID, Punt CJA. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009; 361: 98-99.
4. Italiano A, Hostein I, Soubeyran I et al. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol 2010; 17: 1429-1434.
5. A'Hern RP. Sample size tables for exact single-stage phase II designs. Stat Med 2001; 20: 859-866.